Phase 1 randomized, double-blind, placebo-controlled, single-ascending dose, adaptive design clinical study of SAB-142 in healthy volunteers and participants with T1D.

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 31 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

28 Jan 2025 According to a SAB Biotherapeutics media release, Based on the data from this trial, SAB BIO plans to advance SAB-142 into a Phase 2b trial in 2025 to evaluate the therapeutic candidate in adult and pediatric patients with new-onset T1D.
23 Jan 2025 According to a SAB Biotherapeutics media release, Results from this study will be presented in an R&D webinar event Tuesday, January 28, 2025 at 8:00 am ET.
23 Jan 2025 Results presented in the SAB BIO Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com